IP Library Granted Patent US 7,786,289
Granted Patent B2
US 7,786,289 · App. 10/843,799 · Granted Aug 31, 2010

Method and kit for identifying antibiotic-resistant microorganisms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,786,289
App. No.
10/843,799
Granted
Aug 31, 2010
Kind
B2
Abstract

The invention provides a rapid sample-processing method for preparing hybridization reaction mixtures substantially depleted of RNA, and a method of identifying the methicillin-resistance status and vancomycin-resistance status of an organism.

Claims (22)

1. A device for detecting nucleic acids encoding resistance to an antibiotic, comprising: a solid support and a plurality of detectably labeled solution-phase hybridization probes distributed among a plurality of loci thereon, said plurality of loci comprising, a first locus that comprises one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of bacteria in the genus Staphylococcus , comprising Staphylococcus aureus and Staphylococcus epidermidis , but do not hybridize to ribosomal nucleic acids of bacteria in the genus Enterococcus , a second locus that comprises (a) one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of bacteria in the genus Enterococcus , comprising Enterococcus faecalis and Enterococcus faecium , but not Staphylococcus aureus or any other bacteria in the genus Staphylococcus , and (b) at least one probe that hybridizes to ribosomal nucleic acids from Staphylococcus aureus but not from other species in the genus Staphylococcus or bacteria in the genus Enterococcus , a third locus that comprises a probe mix containing a first mecA probe that comprises SEQ ID NO:2 or the complement thereof, a second mecA probe that comprises SEQ ID NO:3 or the complement thereof, and a third mecA probe that comprises SEQ ID NO:5 or the complement thereof, and a fourth locus that comprises a probe mix containing probes that collectively hybridize to VanA nucleic acids and to VanB nucleic acids, wherein said probe mix of said fourth locus has nucleotide sequences that consists of the nucleotide sequences SEQ ID NO:27 or the complement thereof, SEO ID NO :28 or the complement thereof, SEQ ID NO:29 or the complement thereof, SEQ ID NO:30 or the complement thereof, SEQ ID NO:40 or the complement thereof, and SEQ ID NO:41 or the complement thereof.

2. The device of claim 1 , wherein each of said detectably labeled solution-phase hybridization probes is labeled with a homogeneously detectable label.

3. The device of claim 2 , wherein said homogeneously detectable label is a chemiluminescent label.

4. The device of claim 1 , further comprising a fifth locus, said fifth locus comprising one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of Gram-positive bacteria comprising the high(G+C) subset thereof, a plurality of species of bacteria in the family Enterobacteriaceae , a plurality of species of bacteria in the genus Enterococcus , and a plurality of species of bacteria in the genus Staphylococcus.

5. A device for detecting nucleic acids encoding resistance to an antibiotic, comprising: a solid support and a plurality of detectably labeled solution-phase hybridization probes distributed among at least five loci thereon, comprising, a first locus that comprises one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of bacteria in the genus Staphylococcus , comprising Staphylococcus aureus, Staphylococcus intermedius and Staphylococcus epidermidis , a second locus that comprises a probe that hybridizes to ribosomal nucleic acids from Staphylococcus aureus but not other species in the genus Staphylococcus , a third locus that comprises a probe mix comprising SEQ ID NO:2 or the complement thereof, SEQ ID NO:3 or the complement thereof, and SEQ ID NO:5 or the complement thereof, a fourth locus that comprises one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of Gram-positive bacteria comprising the high(G+C) subset thereof, a plurality of species of bacteria in the family Enterobacteriaceae , a plurality of species of bacteria in the genus Enterococcus , and a plurality of species of bacteria in the genus Staphylococcus ; and a fifth locus that comprises a probe mix containing probes that collectively hybridize to VanA nucleic acids and to VanB nucleic acids, wherein said probe mix of said fifth locus has nucleotide sequences that consists of the nucleotide sequences SEQ ID NO:27 or the complement thereof, SEQ ID NO:28 or the complement thereof, SEQ ID NO:29 or the complement thereof, SEQ ID NO:30 or the complement thereof, SEQ ID NO:40 or the complement thereof, and SEQ ID NO:41 or the complement thereof.

6. The device of claim 5 , wherein said one or more probes of said fourth locus comprise a pan-bacterial probe of the base sequence of SEQ ID NO:16.

7. A device for detecting nucleic acids encoding resistance to an antibiotic, comprising: a solid support and a plurality of detectably labeled solution-phase hybridization probes distributed among a plurality of loci thereon, said plurality of loci comprising, a first locus that comprises one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of bacteria in the genus Enterococcus , comprising Enterococcus faecalis and Enterococcus faecium , a second locus that comprises a probe mix containing probes that collectively hybridize to VanA nucleic acids and to VanB nucleic acids, wherein said probe mix of said second locus has nucleotide sequences that consists of the nucleotide sequences SEQ ID NO:27 or the complement thereof, SEQ ID NO:28 or the complement thereof, SEQ 1D NO:29 or the complement thereof, SEQ ID NO:30 or the complement thereof, SEQ ID NO:40 or the complement thereof, and SEQ ID NO:41 or the complement thereof, and a third locus that comprises one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of Gram-positive bacteria comprising the high(G+C) subset thereof, a plurality of species of bacteria in the family Enterobacteriaceae , a plurality of species of bacteria in the genus Enteroeoccus , and a plurality of species of bacteria in the genus Staphylococcus .

8. The device of claim 7 , wherein said one or more probes of said third locus comprise a pan-bacterial probe of SEQ ID NO:16.

9. The device of claim 1 , wherein the first mecA probe of said probe mix consists of SEQ ID NO:2 or the complement thereof, wherein the second mecA probe of said probe mix consists of SEQ ID NO:3 or the complement thereof, and wherein the third mecA probe of said probe mix consists of SEQ ID NO:5 or the complement thereof.

10. The device of claim 9 , wherein the first mecA probe of said probe mix consists of SEQ ID NO:2, wherein the second mecA probe of said probe mix consists of SEQ ID NO:3, and wherein the third mecA probe of said probe mix consists of SEQ ID NO:5.

11. A device for detecting nucleic acids encoding resistance to an antibiotic, comprising: a solid support and a plurality of immobilized detectably labeled probes distributed among a plurality of loci thereon, said plurality of loci comprising, a first locus that comprises one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of bacteria in the genus Staphylococcus , comprising Staphylococcus aureus and Staphylococcus epidermidis , but do not hybridize to ribosomal nucleic acids of bacteria in the genus Enterococeus , a second locus that comprises (a) one or more probes that collectively hybridize to ribosomal nucleic acids from a plurality of bacteria in the genus Enterococcus , comprising Enterococcus faecalis and Enterococcus faecium , but not Staphylococcus aureus or any other bacteria in the genus Staphylococcus , and (b) at least one probe that hybridizes to ribosomal nucleic acids from Staphylococcus aureus but not from other species in the genus Staphylococcus or bacteria in the genus Enterococcus , a third locus that comprises a probe mix wherein said probe mix comprises a first mecA probe that comprises SEQ ID NO:2 or the complement thereof, a second mecA probe that comprises SEQ ID NO:3 or the complement thereof, and a third mecA probe that comprises SEQ ID NO:5 or the complement thereof, and a fourth locus that comprises a probe mix containing probes that collectively hybridize to VanA nucleic acids and to VanB nucleic acids, wherein said probe mix of said fourth locus has nucleotide sequences that consists of the nucleotide sequences SEQ ID NO:27 or the complement thereof, SEQ ID NO:28 or the complement thereof, SEQ ID NO:29 or the complement thereof, SEQ ID NO:30 or the complement thereof, SEQ ID NO:40 or the complement thereof, and SEQ ID NO:41 or the complement thereof.

12. The device of claim 11 , wherein each of said plurality of immobilized detectably labeled probes comprises a detectable label prior to contact with a biological sample to be tested for the presence of microorganisms or nucleic acids thereof.

13. The device of claim 1 , wherein each of said plurality of detectably labeled solution-phase hybridization probes comprises a detectable label prior to contact with a biological sample to be tested for the presence of microorganisms or nucleic acids thereof.

14. The device of claim 7 , wherein each of said plurality of detectably labeled solution-phase hybridization probes comprises a detectable label prior to contact with a biological sample to be tested for the presence of microorganisms or nucleic acids thereof.

15. The device of claim 5 , wherein the probe mix consists of the nucleotide sequences SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO: 5.

16. The device of claim 5 , wherein each of said plurality of detectably labeled solution-phase hybridization probes comprises a detectable label prior to contact with a biological sample to be tested for the presence of microorganisms or nucleic acids thereof.

17. The device of claim 11 , wherein the first mecA probe of said probe mix consists of SEQ ID NO:2 or the complement thereof, wherein the second mecA probe of said probe mix consists of SEQ ID NO:3 or the complement thereof, and wherein the third mecA probe of said probe mix consists of SEQ ID NO:5 or the complement thereof.

18. The device of claim 17 , wherein the first mecA probe of said probe mix consists of SEQ ID NO:2, wherein the second mecA probe of said probe mix consists of SEQ ID NO:3, and wherein the third mecA probe of said probe mix consists of SEQ ID NO:5.

19. The device of claim 1 , wherein said plurality of loci are wells of a multi-well plate.

20. The device of claim 5 , wherein said plurality of loci are wells of a multi-well plate.

21. The device of claim 7 , wherein said plurality of loci are wells of a multi-well plate.

22. The device of claim 11 , wherein said plurality of loci are wells of a multi-well plate.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2004
From: HOGAN, JAMES J.; KAPLAN, SHANNON K.
To: GEN-PROBE INCORPORATED
Reel/Frame 014684/0667 →